Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: Results from the DANBIO registry

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2130-2136

  Højgaard, Pil ^a,b   Glintborg, Bente ^a,c   Hetland, Merete Lund ^c,d   Hansen, Torben Højland ^e   Lage Hansen, Philip Rask ^f   Petersen, Martin H ^g   Holland Fischer, Mette ^h   Nilsson, Christine ⁱ   Loft, Anne Gitte ^j   Andersen, Bjarne Nesgaard ^k   Adelsten, Thomas ^l   Jensen, Jørgen ^m   Omerovic, Emina ^c   Christensen, Regitse ^a   Tarp, Ulrik ⁿ   Østgård, René ^o   Dreyer, Lene ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HOLBÆK HOSPITAL   (Denmark)

^f University of Esbjerg   (Denmark)

^g SVENDBORG HOSPITAL   (Denmark)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j LILLEBAELT HOSPITAL   (Denmark)

^k University of Copenhagen   (Denmark)

^l HILLERØD HOSPITAL   (Denmark)

^m KØGE HOSPITAL   (Denmark)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o SILKEBORG REGIONAL HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DANE (PEOPLE); DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SMOKING; VISUAL ANALOG SCALE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; METABOLISM; MIDDLE AGED; REGISTER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RETROSPECTIVE STUDIES; SMOKING; TREATMENT OUTCOME;

EID: 84954364041     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205389     Document Type: Article

References (44)

1. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
2. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
3. Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
4. Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
5. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
6. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65.
7. Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012;71:804-8.
8. Eder L, Shanmugarajah S, Thavaneswaran A, et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012;71:219-24.
9. Haroon M, Petty-Saphon N, Gallagher P, et al. Clinical and patient-reported outcome measures as predictors of poor functional outcome in psoriatic arthritis [Abstract]. Ann Rheum Dis 2013;72(Suppl3):682.
10. Miller S, Bawa S. The effect of smoking on treatment response and drug survival in psoriatic arthritis patients treated with their first anti-TNFa drug: a single-centre restrospective analysis [Abstract]. Ann Rheum Dis 2013;72(Suppl3):686.
11. Haddad A, Thavaneswaran A, Ruiz Arruza R, et al. Psoriatic arthritis on TNF blockers [Abstract]. Ann Rheum Dis 2013;72(Suppl3):675.
12. Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132-7.
13. Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013;72:1358-61.
14. Chung HY, Machado P, van der Heijde D, et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012;71:809-16.
15. Mattey DL, Dawson SR, Healey EL, et al. Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 2011;38:2608-15.
16. Poddubnyy D, Haibel H, Listing J, et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis 2013;72:1430-2.
17. Manfredsdottir VF, Vikingsdottir T, Jonsson T, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006;45:734-40.
18. Papadopoulos NG, Alamanos Y, Voulgari PV, et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005;23:861-6.
19. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008;47:849-54.
20. Abhishek A, Butt S, Gadsby K, et al. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010;16:15-8.
21. Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63:26-36.
22. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009;36:1180-7.
23. Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012;41:1-9.
24. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013;65:1213-23.
25. Hetland ML, Unkerskov J, Ravn T, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005;34:40-4.
26. Hetland ML, Lindegaard HM, Hansen A, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
27. Hetland ML. DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford) 2011;50:69-77.
28. Schefte DB, Hetland ML. An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) 2010;49:99-104.
29. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
30. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinalstudy of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
31. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
32. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
33. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
34. Leeb BF, Andel I, Sautner J, et al. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256-60.
35. Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:1223-9.
36. Park SJ, Shin JI. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: comments on the article by Soderlin et al. Scand J Rheumatol 2012;41:411-2.
37. Metsios GS, Stavropoulos-Kalinoglou A, Nevill AM, et al. Cigarette smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:70-3.
38. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-38.
39. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
40. Danskernes rygevaner 2012. Tabelrapport for hele befolkningen. Danish Health and Medicines Authority. http://sundhedsstyrelsen.dk/~/media/29DD77B5D497489F99D75F1AC757862E.ashx. 2012. (GENERIC)
41. Berner O, Etwil P, Graversen T, et al. 50 års oversigten. Danmarks statistik. 2001. http://www.dst.dk/pukora/epub/upload/3189/halvtres.pdf
42. Di Lernia V, Ricci C, Lallas A, et al. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat 2014;25:73-4.
43. Attwa E, Swelam E. Relationship between smoking-induced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2011;25:782-7.
44. Emre S, Metin A, Demirseren DD, et al. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2013;27:e370-5.